In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 mice

Experimental Neurology

Volumn 232, Issue 2, 2011, Pages 290-298

  Öz, Gülin ^a   Vollmers, Manda L ^a   Nelson, Christopher D ^a   Shanley, Ryan ^b   Eberly, Lynn E ^b   Orr, Harry T ^a   Clark, H Brent ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cerebellum; Mouse model; MRS; Neurodegeneration; SCA1

Indexed keywords

CREATININE; DOXYCYCLINE; INOSITOL; N ACETYLASPARTIC ACID; TAURINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY ANALYSIS; SPINOCEREBELLAR DEGENERATION; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; ANTI-BACTERIAL AGENTS; CEREBELLUM; DISEASE MODELS, ANIMAL; DOXYCYCLINE; DRUG MONITORING; FEMALE; GENE EXPRESSION; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; PROTONS; RECOVERY OF FUNCTION; SPINOCEREBELLAR ATAXIAS; TRANSGENES;

EID: 80055009918     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.09.021     Document Type: Article

References (44)

1. Allegrini P.R., Sauer D. Application of magnetic resonance imaging to the measurement of neurodegeneration in rat brain: MRI data correlate strongly with histology and enzymatic analysis. Magn. Reson. Imaging 1992, 10:773-778.
2. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., Friedlich A., Browne S.E., Schilling G., Borchelt D.R., Hersch S.M., Ross C.A., Beal M.F. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 2001, 8:479-491.
3. Bender A., Auer D.P., Merl T., Reilmann R., Saemann P., Yassouridis A., Bender J., Weindl A., Dose M., Gasser T., Klopstock T. Creatine supplementation lowers brain glutamate levels in Huntington's disease. J. Neurol. 2005, 252:36-41.
4. Brand A., Richter-Landsberg C., Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev. Neurosci. 1993, 15:289-298.
5. Chen W.Q., Jin H., Nguyen M., Carr J., Lee Y.J., Hsu C.C., Faiman M.D., Schloss J.V., Wu J.Y. Role of taurine in regulation of intracellular calcium level and neuroprotective function in cultured neurons. J. Neurosci. Res. 2001, 66:612-619.
6. Choi J.K., Jenkins B.G., Carreras I., Kaymakcalan S., Cormier K., Kowall N.W., Dedeoglu A. Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp. Neurol. 2010, 223:377-384.
7. Clark J.B. N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev. Neurosci. 1998, 20:271-276.
8. Clark H.B., Burright E.N., Yunis W.S., Larson S., Wilcox C., Hartman B., Matilla A., Zoghbi H.Y., Orr H.T. Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations. J. Neurosci. 1997, 17:7385-7395.
9. Dedeoglu A., Choi J.K., Cormier K., Kowall N.W., Jenkins B.G. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 2004, 1012:60-65.
10. DeKosky S.T., Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003, 302:830-834.
11. 1 shimming. NMR Biomed 2011, 10.1002/nbm.1727.
12. Ernst T., Kreis R., Ross B.D. Absolute quantitation of water and metabolites in the human brain. I. Compartments and water. J. Magn. Reson. 1993, 102:1-8.
13. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 2000, 20:4389-4397.
14. Fisher S.K., Novak J.E., Agranoff B.W. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J. Neurochem. 2002, 82:736-754.
15. Garwood M., DelaBarre L. The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. J. Magn. Reson. 2001, 153:155-177.
16. Gruetter R., Tkáč I. Field mapping without reference scan using asymmetric echo-planar techniques. Magn. Reson. Med. 2000, 43:319-323.
17. Hennig J., Nauerth A., Friedburg H. RARE imaging: a fast imaging method for clinical MR. Magn. Reson. Med. 1986, 3:823-833.
18. Holm S. A simple sequentially rejective Bonferroni test procedure. Scand. J. Stat. 1979, 6:65-70.
19. Jenkins B.G., Klivenyi P., Kustermann E., Andreassen O.A., Ferrante R.J., Rosen B.R., Beal M.F. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J. Neurochem. 2000, 74:2108-2119.
20. Kalra S., Arnold D.L. ALS surrogate markers. MRS. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2004, 5(Suppl 1):111-114.
21. 1H MR spectroscopy metabolite measurements. Radiology 2008, 248:210-220.
22. Marjanska M., Curran G.L., Wengenack T.M., Henry P.G., Bliss R.L., Poduslo J.F., Jack C.R., Ugurbil K., Garwood M. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11906-11910.
23. Mueller S.G., Schuff N., Weiner M.W. Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS. NMR Biomed. 2006, 19:655-668.
24. Nagae-Poetscher L.M., Bonekamp D., Barker P.B., Brant L.J., Kaufmann W.E., Horska A. Asymmetry and gender effect in functionally lateralized cortical regions: a proton MRS imaging study. J. Magn. Reson. Imaging 2004, 19:27-33.
25. Niessen H.G., Debska-Vielhaber G., Sander K., Angenstein F., Ludolph A.C., Hilfert L., Willker W., Leibfritz D., Heinze H.J., Kunz W.S., Vielhaber S. Metabolic progression markers of neurodegeneration in the transgenic G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Eur. J. Neurosci. 2007, 25:1669-1677.
26. Orr H.T., Chung M.Y., Banfi S., Kwiatkowski T.J., Servadio A., Beaudet A.L., McCall A.E., Duvick L.A., Ranum L.P., Zoghbi H.Y. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat. Genet. 1993, 4:221-226.
27. Ottersen O.P. Quantitative assessment of taurine-like immunoreactivity in different cell types and processes in rat cerebellum: an electronmicroscopic study based on a postembedding immunogold labelling procedure. Anat. Embryol. (Berl.) 1988, 178:407-421.
28. Öz G., Tkáč I. Short-echo, single-shot, full-intensity proton magnetic resonance spectroscopy for neurochemical profiling at 4T: validation in the cerebellum and brainstem. Magn. Reson. Med. 2011, 65:901-910.
29. Öz G., Tkáč I., Charnas L.R., Choi I.Y., Bjoraker K.J., Shapiro E.G., Gruetter R. Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients. Neurology 2005, 64:434-441.
30. Öz G., Hutter D., Tkáč I., Clark H.B., Gross M.D., Jiang H., Eberly L.E., Bushara K.O., Gomez C.M. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov. Disord. 2010, 25:1253-1261.
31. Öz G., Nelson C.D., Koski D.M., Henry P.G., Marjańska M., Deelchand D.K., Shanley R., Eberly L.E., Orr H.T., Clark H.B. Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J. Neurosci. 2010, 30:3831-3838.
32. Pouwels P.J., Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn. Reson. Med. 1998, 39:53-60.
33. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993, 30:672-679.
34. Provencher S.W. LCModel & LCMgui User's Manual 2001.
35. Schmitz-Hübsch T., Fimmers R., Rakowicz M., Rola R., Zdzienicka E., Fancellu R., Mariotti C., Linnemann C., Schöls L., Timmann D., Filla A., Salvatore E., Infante J., Giunti P., Labrum R., Kremer B., van de Warrenburg B.P., Baliko L., Melegh B., Depondt C., Schulz J., du Montcel S.T., Klockgether T. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 2010, 74:678-684.
36. Sturman J.A., Moretz R.C., French J.H., Wisniewski H.M. Postnatal taurine deficiency in the kitten results in a persistence of the cerebellar external granule cell layer: correction by taurine feeding. J. Neurosci. Res. 1985, 13:521-528.
37. Taranukhin A.G., Taranukhina E.Y., Saransaari P., Podkletnova I.M., Pelto-Huikko M., Oja S.S. Neuroprotection by taurine in ethanol-induced apoptosis in the developing cerebellum. J. Biomed. Sci. 2010, 17(Suppl. 1):S12.
38. 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn. Reson. Med. 1999, 41:649-656.
39. 1H NMR spectroscopy. J. Neurochem. 2007, 100:1397-1406.
40. van Gelder N.M. Brain taurine content as a function of cerebral metabolic rate: osmotic regulation of glucose derived water production. Neurochem. Res. 1989, 14:495-497.
41. van Vlieta S.A., Blezer E.L., Jongsma M.J., Vanwersch R.A., Olivier B., Philippens I.H. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy. Brain Res. 2008, 1189:219-228.
42. von Kienlin M., Kunnecke B., Metzger F., Steiner G., Richards J.G., Ozmen L., Jacobsen H., Loetscher H. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol. Dis. 2005, 18:32-39.
43. Wu J.Y., Prentice H. Role of taurine in the central nervous system. J. Biomed. Sci. 2010, 17(Suppl. 1):S1.
44. Zu T., Duvick L.A., Kaytor M.D., Berlinger M.S., Zoghbi H.Y., Clark H.B., Orr H.T. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 2004, 24:8853-8861.